Analyst Expectations for Neurocrine Biosciences’s Future
Over the past 3 months, 22 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:NBIX) stock. These analysts…
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in pre-market trading.
What’s Going On With Neurocrine Biosciences Stock Today?
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Neurocrine Biosciences Presents Data At MDS International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Comparable Improvement Over Time In Tardive Dyskinesia Severity And Impact Following Treatment With INGREZZA Capsules
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today presented findings from a data analysis of KINECT®-4 demonstrating a comparable pattern of improvement over time of clinician-rated tardive dyskinesia (TD)
FDA Greenlights Expanded Use Of Neurocrine Biosciences’ Ingrezza: Analysts Weigh In Depression Warning
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated
Analyst Ratings for Neurocrine Biosciences
Over the past 3 months, 16 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:NBIX) stock. These analysts…
Neurocrine Biosciences Announces FDA Approval Of INGREZZA Capsules For The Treatment Of Chorea Associated With Huntington’s Disease
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated
Analyst Ratings for Neurocrine Biosciences
Over the past 3 months, 13 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:NBIX) stock. These analysts…
Earnings Scheduled For August 1, 2023
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is estimated to report earnings for its first quarter.
• BP (NYSE:BP) is projected to report quarterly earnings at $1.21 per share on revenue of $54.48 billion.